Clinical Trial Update: A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial (ADEPT-1, NCT05511363) evaluating KarXT for psychosis associated with Alzheimer's disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Conditions: Psychosis Associated With Alzheimer's Disease | Phase 3 | Status: RECRUITING